The Library

Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?

Tools

McIntyre, Dominick J. O., Howe, Franklyn A., Ladroue, Christophe, Lofts, Fiona, Stubbs, Marion and Griffiths, John R.. (2011) Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? Cancer Chemotherapy and Pharmacology, Vol.68 (No.1). pp. 29-36. ISSN 0344-5704

Preview

PDF
WRAP_Lofts_fulltext.pdf - Published Version - Requires a PDF viewer.
Download (273Kb)

Official URL: http://dx.doi.org/10.1007/s00280-010-1438-2

Abstract

Background 5-Fluorouracil remains widely used in
colorectal cancer treatment more than 40 years after its
development. 19F magnetic resonance spectroscopy can be
used in vivo to measure 5FU’s half-life and metabolism to
cytotoxic fluoronucleotides. Previous studies have shown
better survival associated with longer 5FU tumour half-life.
This work investigated 5FU pharmacokinetics in liver
metastases of colorectal cancer.
Methods A total of 32 subjects with colorectal cancer
undergoing 5FU treatment, 15 of whom had liver metastases,
were examined in a 1.5T MRI scanner, using a large
coil positioned over the liver. Non-localised spectra were
acquired in 1-min blocks for 32 min after injection of a
5FU bolus. The 5FU half-life was measured in each subject,
and averaged spectra were examined for the presence
of fluoronucleotides. Associations with progression-free
survival were assessed.
Results No association was observed between 5FU halflife,
tumour burden and survival. Half-lives were all shorter
than those associated with improved survival in the literature.
Remarkably, in the group with liver metastases, high
levels of fluoronucleotides were associated with poorer
survival; this counterintuitive result may be due to the
higher levels of fluoronucleotides (whose level is higher in
tumour tissue than in normal liver) in patients with higher
tumour burdens.
Conclusions It is recommended that future studies use
chemical shift imaging at higher field strengths to better
resolve tumour from normal liver. Non-localised spectroscopy
retains prognostic potential by enabling straightforward
detection of fluoronucleotides, which are present at
very low concentrations distributed throughout the tissue.

Item Type:

Journal Article

Subjects:

R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)

Divisions:

Faculty of Science > Statistics

Library of Congress Subject Headings (LCSH):

Colon (Anatomy) -- Cancer -- Treatment, Rectum -- Cancer -- Treatment, Fluorouracil, Metastasis

Journal or Publication Title:

Cancer Chemotherapy and Pharmacology

Publisher:

Springer

ISSN:

0344-5704

Official Date:

2011

Dates:

Date	Event
2011	Published

Volume:

Vol.68

Number:

No.1

Page Range:

pp. 29-36

Identifier:

10.1007/s00280-010-1438-2

Status:

Peer Reviewed

Access rights to Published version:

Open Access

Funder:

University of Cambridge, Cancer Research UK (CRUK), Hutchison Whampoa Ltd.

References:

1. Segal NH, Saltz LB (2009) Evolving treatment of advanced colon
cancer. Annu Rev Med 60:207–219
2. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P,
Blayney D, Brechner RR (1994) Association of intratumoral
pharmacokinetics of fluorouracil with clinical response. Lancet
343:1184–1187
3. Findlay MPN, Raynaud F, Cunningham D, Iveson A, Collins DJ,
Leach MO (1996) Measurement of plasma 5-fluorouracil by highperformance
liquid chromatography with comparison of results to
tissue drug levels observed using in vivo 19F magnetic resonance
spectroscopy in patients on a protracted venous infusion with or
without interferon-a. Ann Oncol 7:47–53
4. Wolf W, Presant CA, Servis KL, El-Tahtawy A, Albright MJ,
Barker PB, Ring R III, Atkinson D, Ong R, King M, Singh M,
Ray M, Wiseman C, Blayney D, Shani J (1990) Tumor trapping
of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics
in tumor-bearing humans and rabbits. Proceedings of the
National Academy of Sciences 87:492–496
5. Wolf W, Waluch V, Presant CA (1998) Non-invasive F-19-
NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic
studies. NMR Biomed 11:380–387
6. Wolf W, Presant CA, Waluch V (2000) 19F-MRS studies of
fluorinated drugs in humans. Adv Drug Deliv Rev 41:55–74
7. Kamm YJL, Heerschap A, van den Bergh EJ, Wagener DJT
(2004) 19F-magnetic resonance spectroscopy in patients with
liver metastases of colorectal cancer treated with 5-fluorouracil.
Anti-Cancer Drugs 15:229–233
8. van Laarhoven HWM, Klomp DWJ, Rijpkema M, Kamm YLM,
Wagener DJT, Barentsz JO, Punt CJA, Heerschap A (2007)
Prediction of chemotherapeutic response of colorectal liver
metastases with dynamic gadolinium-DTPA-enhanced MRI and
localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
NMR Biomed 20:128–140
9. Stevens AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR
(1984) 5-fluorouracil metabolism monitored in vivo by 19F
NMR. Br J Cancer 50:113–117
10. McSheehy PMJ, Robinson SP, Ojugo ASE, Aboagye EO, Cannell
MB, Leach MO, Judson IR, Griffiths JR (1998) Carbogen
breathing increases 5-fluorouracil uptake and cytotoxicity in
hypoxic murine RIF-1 tumors: a magnetic resonance study in
vivo. Cancer Res 58:1185–1194
11. Sijens PE, Huang Y, Baldwin NJ, Ng TC (1991) 19F Magnetic
resonance spectroscopy studies of the metabolism of 5-fluorouracil
in murine rif-1 tumors and liver. Cancer Res 51:1384–1390
12. McSheehy PM, Prior MJ, Griffiths JR (1989) Prediction of 5-
fluorouracil cytotoxicity towards the Walker carcinosarcoma
using peak integrals of fluoronucleotides measured by MRS in
vivo. Br J Cancer 60:303–309
13. Doi Y, Shimmura T, Kuribayashi H, Tanaka Y, Kanazawa Y
(2009) Quantitative 19F imaging of nmol-level F-nucleotides/-
sides from 5-FU with T2 mapping in mice at 9.4T. Magn Reson
Med 62:1129–1139
14. Findlay MP, Leach MO (1994) In vivo monitoring of fluoropyrimidine
metabolites: magnetic resonance spectroscopy in the
evaluation of 5-fluorouracil. Anti-Cancer Drugs 5:260–280
15. Naressi A, Couturier C, Devos JM, Janssen M, Mangeat C, de
Beer R, Graveron-Demilly D (2001) Java-based graphical user
interface for the MRUI quantitation package. MAGMA
12:141–152
16. Vanhamme L, van den Boogaart A, Van Huffel S (1997)
Improved method for accurate and efficient quantification of
MRS data with use of prior knowledge. J Magn Reson 129:35–43
17. Kamm YJL, Heerschap A, Wagener DJT (2000) Effect of carbogen
breathing on the pharmacodynamics of 5-fluorouracil in a
murine colon carcinoma. Eur J Cancer 36:1180–1186
18. Griffiths JR, McIntyre DJO, Howe FA, McSheehy PMJ, Ojugo
ASE, Rodrigues LM, Wadsworth P, Price NM, Lofts F,
Nicholson G, Smid K, Noordhuis P, Peters GJ, Stubbs M (2001)
Issues of normal tissue toxicity in patient and animal studies—
Effect of carbogen breathing in rats after 5-fluorouracil treatment.
Acta Oncol 40:609–614
19. Ojugo ASE, McSheehy PMJ, Stubbs M, Alder G, Bashford CL,
Maxwell RJ, Leach MO, Judson IR, Griffiths JR (1998) Influence
of pH on the uptake of 5-fluorouracil into isolated tumour cells.
Br J Cancer 77:873–879
20. Guerquin-Kern J-L, Leteurtre F, Croisy A, Lhoste J-M (1991) pH
Dependence of 5-fluorouracil uptake observed by in vivo 31p and
19f nuclear magnetic resonance spectroscopy. Cancer Res
51:5770–5773
21. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR (1999) Flow
and oxygenation dependent (FLOOD) contrast MR imaging to
monitor the response of rat tumors to carbogen breathing. Magn
Reson Imaging 17:1307–1318
22. Honess DJ, Bleehen NM (1995) Perfusion changes in the RIF-1
tumour and normal tissues after carbogen and nicotinamide,
individually and combined. Br J Cancer 71:1175–1180
23. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, Phillips R,
Vernon C, Wasan H, Jones T, Hoskin PJ, Price PM (2006)
Carbogen and nicotinamide increase blood flow and 5-fluorouracil
delivery but not 5-fluorouracil retention in colorectal cancer
metastases in patients. Clin Cancer Res 12:3115–3123
24. van Laarhoven HWM, Gambarota G, Lok J, Lammens M, Kamm
YLM, Wagener T, Punt CJA, van der Kogelz AJ, Heerschap A
(2006) Carbogen breathing differentially enhances blood plasma
volume and 5-fluorouracil uptake in two murine colon tumor
models with a distinct vascular structure. Neoplasia 8:477–487
25. van Laarhoven HWM, Klomp DWJ, Kamm YJL, Punt CJA,
Heerschap A (2003) In vivo monitoring of capecitabine metabolism
in human liver by 19fluorine magnetic resonance spectroscopy
at 1.5 and 3 tesla field strength. Cancer Res
63:7609–7612
26. Klomp DWJ, van Laarhoven HWM, Scheenen T, Kamm YJL,
Heerschap A (2007) Quantitative 19F MR spectroscopy at 3 T to
detect heterogeneous capecitabine metabolism in human liver.
NMR Biomed 20:485–492